Drug intelligence / Profile preview

Inno 8

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Oral

Overview

Inno 8 is an investigational, VHH-based Factor VIIIa mimetic designed to replace or mimic Factor VIII activity for the treatment of haemophilia A. It is described as a novel single-domain antibody recombinant protein with ultrahigh potency, being developed for once-daily oral administration, with both single-ascending-dose and multiple-ascending-dose evaluations in Phase 1 healthy volunteer studies intended to support development in haemophilia A patients.[5][3][1]

Other names: Inno 8Inno8Inno-8

Targets

F10 (Factor Xa)Coagulation Factor IXa

Beyond the preview

Go deeper on Inno 8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inno 8.

Explore the full profile